Wedbush analyst Andreas Argyrides raised the firm’s price target on Ascendis Pharma to $225 from $207 and keeps an Outperform rating on the shares. The firm says YORVIPATH launches in Germany and Austria, and recent survey support robust uptake. Ascendis is on Wedbush’s Best Ideas List and is one of its top picks for 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ASND:
- Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results
- Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Is ASND a Buy, Before Earnings?
- Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024
- Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism
